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Luminal fluid homeostasis in the respiratory system is crucial to maintain the gas-
blood exchange in normal lungs and mucociliary clearance in the airways. Epithelial 
sodium channels (ENaC) govern ~70% of alveolar fluid clearance. Four ENaC subunits 
have been cloned, namely, α, β, γ, and δ ENaC subunits in mammalian cells. This 
critical review focuses on the expression and function of ENaC in human and murine 
lungs, and the post-translational regulation by fibrinolysins. Nebulized urokinase was 
intratracheally delivered for clinical models of lung injury with unknown mechanisms. 
The central hypothesis is that proteolytically cleaved ENaC channels composed of four 
subunits are essential pathways to maintain fluid homeostasis in the airspaces, and that 
fibrinolysins are potential pharmaceutical ENaC activators to resolve edema fluid. This 
hypothesis is strongly supported by our following observations: 1) δ ENaC is expressed 
in the apical membrane of human lung epithelial cells; 2) δ ENaC physically interacts 
with the other three ENaC counterparts; 3) the features of αβγ ENaC channels are 
conferred by δ ENaC; 4) urokinase activates ENaC activity; 5) urokinase deficiency is 
associated with a markedly distressed pulmonary ENaC function in vivo; 6) γ ENaC is 
proteolytically cleaved by urokinase; 7) urokinase augments the density of opening 
channels at the cell surface; and 8) urokinase extends opening time of ENaC channels 
to the most extent. Our integrated publications laid the groundwork for an innovative 
concept of pulmonary transepithelial fluid clearance in both normal and diseased lungs.   
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Figure 1. Polygenetic tree of the ENaC/DEG superfamily. ENaC, epithelial sodium 
channels; ASIC, acid sensing ion channels; NaC, sodium channels; DEG, 
degenerins. 
1. Introduction 
This review explores a central thread in the ideas and publications generated in 
the last two decade by myself and by prolific collaborations with my colleagues. I 
initiated my studies in amiloride-sensitive epithelial sodium transport in 1995 while I was 
trained as a postdoctoral fellow in the University of Georgia at Athens. I extended my 
research to understand the structure-function relationship of α, β, and γ ENaC 
combining mutagenesis and heterologous expression in a well-established 3-D cell 
model, Xenopus oocytes. Subsequently, I cloned three DNA constructs encoding δ 
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ENaC subunits in human lungs (Ji et al., 2006; Zhao et al., 2012), and characterized 
their biophysical and pharmacological features and expression profiles in human lungs 
(Ji et al., 2006; Zhao et al., 2012).  I recently found that fibrinolysins in bronchioalveolar 
lavage are critical regulators of ENaC function. I, for the first time, identified both the 
cleavage sites in human ENaC proteins and the catalytic triad of urokinase (Ji et al., 
2015). This review will summarize the critical findings of these publications.  
The ENaC/DEG super gene family. Human ENaC subunits (α, β, δ, and γ) are 
encoded, respectively, by four genes, namely, scnn1a (sodium channels nonvoltage-
dependent), scnn1b, scnn1d, and scnn1d. These genes are comprised of a branch of 
the super ENaC/DEG gene family with more than a hundred members (Figure 1). The 
name degenerin (DEG) comes from the cellular phenotype induced by mutations of 
deg-1 and other related genes that result in selective degeneration of sensory neurons 
involved in touch sensitivity of C. elegans (Kellenberger & Schild, 2002). ENaC and 
degenerins have substantial sequence homology. The scnn1 genes encoding ENaC 
proteins were first cloned from mouse colon in 1993 (Canessa et al., 1993). Before that, 
there are several names for this type of channels, e.g., amiloride-sensitive sodium 
channels, voltage-independent sodium channels, non-voltage-gated sodium channels, 
amiloride-inhibitable sodium channels, apical sodium channels, etc. to form leaking 
sodium permeation pathway across the apical membrane of polarized epithelium in the 
kidney, the lung, the airways, the colon, the sweat gland, and other tissues. The 
essential function of ENaC is to serve as cation channels with a permeability order: Li+ 
>Na+ >K+ >Cs+. Beside, ENaC as well as other members of the ENaC/DEG family are 
also expressed in non-epithelial cells, including neurons, smooth muscle cells, 
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Figure 2. Gene expression profile of scnn1a, scnn1b, scnn1g, and scnn1d. Expression levels 
are computed from the “GeneAtlas U133A, gcmas” dataset, an atlas of tissue expression 
(GeneAtlas) on an Affymetrix U133A array, using the gcrma algorithm to process the data. 
The y-axes on these graphs represent normalized, background-subtracted, and summarized 
(probes to probeset) intensity of each probe set: 1 kidney, 2 tonsil, 3 lymph node, 4 thymus, 5 
bone marrow, 6 adrenal gland, 7 adrenal cortex, 8 olfactory bulb, 9 trachea, 10 salivary gland, 
11 pituitary, 12 fetal liver, 13 fetal lung, 14 fetal thyroid, 15 uterus, 16 adipocyte, 17 pancreatic 
islet, 18 pancreas, 19 testis seminiferous tubule, 20 testis Leydig cell, 21 testis interstitial, 22 
testis germ cell, 23 testis, 24 colorectal adenocarcinoma, 25 bronchial epithelial cells, 26 
smooth muscle, 27 cardiac myocytes, 28 leukemia lymphoblastic (MOLT-4), 29 leukemia 
chronic myelogenous K-562, 30 lymphoma Burkitts (Daudi), 31 leukemia promyelocytic HL-60, 
32 leukemia Burkitts (Raji), 33 thyroid, 34 prostate, 35 lung, 36 placenta, 37 CD71+ early 
erythroid, 38 small intestine, 39 colon, 40 liver, 41 heart, 42 uterus corpus, 43 appendix, 44 
ovary, 45 dorsal root ganglion, 46 ciliary ganglion, 47 atrioventricular node, 48 skin, 49 
trigeminal ganglion, 50 superior cervical ganglion, 51 tongue, 52 skeletal muscle, 53 retina, 54 
pineal night, 55 pineal day, 56 whole brain, 57 amygdala, 58 prefrontal cortex, 59 spinal cord, 
60 hypothalamus, 61 fetal brain, 62 thalamus, 63 caudate nucleus, 64 parietal lobe, 65 
medulla oblongata, 66 cingulate cortex, 67 occipital lobe, 68 temporal lobe, 69 subthalamic 
nucleus, 70 pons, 71 globus pallidus, 72 cerebellum, 73 cerebellum peduncles, 74 CD34+, 75 
CD105+ endothelial, 76 721 B lymphoblasts, 77 CD19+ B cells (neg._sel.), 78 BDCA4+ 
dendritic cells, 79 CD8+ T cells, 80 CD4+ T cells, 81 CD56+ NK cells, 82 CD33+ myeloid, 83 
CD14+ monocytes, 84 whole blood. The bottom x-axes show the median (M) and the fold 
median level, as indicated by purple lines, and the top x-axes show the relative expression 
level with light gray lines; 176 samples for 84 types of tissues were statistically analyzed. 
These results represent relative expression levels and distribution of four scnn1 genes in 
human tissues. Scnn1a and scnn1b are predominately expressed in the lungs, while the other 
genes are distributed in 84 examined tissues/cells without marked difference. Data are 
adapted from BioGPS with permission (www.BioGPS.org). Adapted from Ji, et al 2012. 
leukocytes, endothelial cells, cardiovascular myocytes, mesothelial cells, and skin  
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(Figure 2).  Their function in non-epithelial tissues is proposed to be involved in acid 
sensing, transduction of mechanical stimuli, and nociceptive pain (Ji et al., 2012).  
 
ENaC is a multimeric protein with a proposed heterotrimeric structure (Figure 3) 
(Jasti et al., 2007). However, our understanding of the architecture of the native ENaC 
proteins is incomplete. Based on heterologous expression studies, α and δ ENaC 
subunits are capable of forming electrically detectable channels, which will be amplified 
up to 2 order in the amplitude of current levels by co-expressing with β and γ 
counterparts. In contrast, in the absence of α or δ ENaC subunit, β and γ ENaC cannot 
form functional channels and are considered as regulatory subunits. So far, scnn1 
genes have been cloned from various species, such as rat, human, cow, mouse, and 
Xenopus laevis. For experimental clarity, murine and human ENaC channels are well 
investigated and widely used as research models. The homology between human and 
rat orthologs of ENaC subunit is about 85% to nearly 100%. The exon–intron 
architecture of the four genes encoding the four subunits of ENaC has remained highly 
conserved despite the divergence of their sequences (Kellenberger & Schild, 2002). 
The proteins that belong to the ENaC/DEG family consist of about 510 to 920 amino 
acid residues (Kellenberger & Schild, 2002; Ji et al., 2012). They are made of an 
intracellular N-terminus region followed by a transmembrane domain, a large 
extracellular loop contributing to approximate 60% of protein mass, a second 
transmembrane segment and a cytosolic C-terminal tail (Figure 3) (Ji et al., 2012). Few 
sequences are completely conserved among the ENaC/DEG family. They include a His-
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Figure 3. Heterotrimeric structure of ENaC proteins. α, β, and γ ENaC subunits are 
in red, yellow, and blue color, respectively.  The lipid bilayer of the plasma 
membrane are shown as dark lines in parallel. There are two transmembrane 
domains (M1 and M2), two intracellular terminal tails (N- and C-), and a huge 
extracellular loop. Adapted from Ji et al 2016. 
Glycine motif located in amino-terminal cytoplasmic domain and the extracellular loop 
contains cysteine rich domains II and III (Kellenberger & Schild, 2002).  
ENaC channels are located in the apical membrane of polarized epithelial cells 
particularly in the kidney, the lungs, and the colon where they mediate Na+ transport 
across tight epithelium. ENaC pathway plays a major role in Na+ and K+ ion 
homeostasis of blood, epithelia and luminal fluids by re-absorption of Na+ ions 
(Stockand et al., 2008). The basic functions of ENaC in polarized epithelial cell are to 
allow vectorial transcellular transport of Na+ ions (Figure 4) (Rossier & Stutts, 2009). 
This transepithelial Na+ ion transport through a cell basically involves two steps: first, 
the large electrochemical gradient for Na+ ions across the apical membrane provides 
the driving force for the entry of Na+ into the cell and second, active Na+ transport 
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across the basolateral membrane is accomplished by the energy-consuming Na+/K+-
ATPase (Rossier & Stutts, 2009). The apical entry of Na+ is blocked by submicromolar 
concentration of amiloride and analogs, which are used as potassium-sparing diuretics 
clinically. Amiloride directly “plugs in” the pore of ENaC channels to eliminate inward 
sodium flow (Kleyman & Cragoe, 1988; Kleyman et al., 1999). Inhibition of renal ENaC 
activity leads to a loss of sodium retention and subsequently dehydration of the body, 
and even causes hypotension. Amiloride is a competitive antagonist that competes with 
aldosterone for intracellular cytoplasmic receptor sites, or by directly blocking ENaC 
channels. This active transepithelial transport of Na+ ions is important for maintaining 
 
Figure 4. Transepithelial Na+ transport vectorially across apically located ENaC and 
Na+/K+-ATPase at the basolateral membrane. Adapted from Hanukoglu 2016 
(Hanukoglu & Hanukoglu, 2016). 
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the composition and the volume of the fluid on either side of the epithelium. In the 
kidney and the colon, which are the target tissues for aldosterone action, the 
transepithelial sodium transport is crucial for the maintenance of blood Na+ and K+ 
levels and their homeostasis. In the airways and the lungs, active transepithelial 
transport of Na+ ions is a major mechanism to keep the mucociliary beating of the 
ciliated epithelial cells and to prevent flooding of the air spaces. 
Pulmonary fluid homeostasis. The airway epithelia absorb Na+ via an 
amiloride-sensitive electrogenic transport. This active Na+ absorption is important for the 
maintenance of the composition of the airway surface liquid (Figure 4). The expression 
of the ENaC subunits along the respiratory epithelium is complex and varies between 
species. In adult rats and humans, the α, β, and γ ENaC subunits are highly expressed 
in small and medium-sized airways. The α and γ subunits but not the β subunits are 
expressed more distally in the lung, which may well correspond to localization in the 
type II alveolar cells. This heterogeneity of the expression of ENaC subunits along the 
airways suggests differential regulation of liquid absorption by channels of various 
subunit compositions (Matalon & O'Brodovich, 1999). 
At birth, amiloride-sensitive, electrogenic Na+ transport is important to clear the 
liquid that fills the alveoli and the airways of the fetal mouse lung. mRNAs for α, β, and γ 
ENaC were detected in the fetal lung around days 15–17 of gestation. Expression of 
ENaC subunits, mainly α and γ ENaC subunits, sharply increased in the late fetal and 
early postnatal life when the lung turned from a secretory to an absorptive organ 
(Thome et al., 2003). The physiological role of ENaC in lung liquid balance was clearly 
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demonstrated in mice in which the α ENaC gene was inactivated by homologous 
recombination. These α ENaC knockout mice died 48 hours after birth from respiratory 
failure due to a severe defect in the clearance of the fetal liquid filling the lungs. These 
studies suggest that at birth α ENaC in the mouse fetal lung is essential for Na+ 
absorption (Hummler et al., 1996). The disruption of the β and γ ENaC gene loci 
resulted in a slower clearance of the fetal lung liquid at birth but did not severely affect 
the blood gas parameters. The β or γ ENaC knockout mice died slightly later than the α 
knockout from severe electrolyte imbalance, namely, hyperkalemia due to deficient 
renal K+ secretion. In humans, the contribution of α ENaC to the clearance of fetal lung 
liquid at birth is still unclear. Very premature infants with respiratory distress syndrome 
had reduced sodium absorption across the respiratory epithelia, as demonstrated by a 
reduced nasal transepithelial potential difference, likely contributing to the pathogenesis 
of this syndrome. However, pseudohypoaldosteronism type I (PHA-I) patients with 
severe disruption of the α ENaC gene leading to near-complete loss of channel function 
had no report of respiratory distress syndrome at birth but showed a more than twofold 
higher liquid volume in airway epithelia than normal individuals. Thus, ENaC function in 
humans does not seem to be limiting at birth for the liquid clearance in the mature fetal 
lung. Differences between species in maturation of the lung, in mucociliary clearance, or 
in ENaC subunit expression in the respiratory epithelium may account for the 
phenotypic differences between humans and mice.  
Of note, mice do not express δ ENaC because the scnn1d is a pseudogene in 
murine. In sharp contrast to the early death of newborn litters of scnn1a knockout mice, 
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Figure 5. The uPA system. uPA, urokinase; tPA, tissue-type plasminogen activator; 
α2-AP, α2-antiplasmin; α2-M, α2-macroglobulin; PAI, plasminogen activator 
inhibitor. 
infants carrying a loss-of-function mutant of human α ENaC did not display a deadly 
distress syndrome caused by lung oedema (Trautmann & Pfeiffer, 1994; Bonny et al., 
1999), indicating that δ ENaC subunit may be a backup of α ENaC counterpart (Ji et al., 
2012). However, surviving children with the genetic deletion of scnn1d, encoding δ 
ENaC proteins, were predisposed to respiratory oedematous disorders and infection 
(Unique, 2008). In addition, numerous pathogens and pollutants decreased ENaC 
expression and function in vitro and in vivo (Ji et al., 2012). On the other hand, cystic 
fibrosis is a phenotype with hyperactive ENaC activity in the airways and the lungs. 
Genetically engineered mice over-expressing either α, β, γ, or all of three (α+β+γ) ENaC 
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subunits had a COPD as well as cystic fibrosis phenotypes (Mall et al., 2004; Zhou et 
al., 2007; Mall et al., 2008; Zhou et al., 2011).  
The urokinase system. Urokinase-type plasminogen activator (uPA) initiates 
fibrinolysis by converting plasminogen to plasmin (Figure 5). In the respiratory system, 
uPA is expressed in the airway epithelium, alveolar epithelial cells, macrophages, and 
pulmonary capillary endothelial layer (Gross et al., 1990; Marshall et al., 1990; 
Takahashi et al., 1992; Nishiuma et al., 2004; Sisson & Simon, 2007; Shetty et al., 
2008). uPA released from these cells is a single-chain molecule (scuPA), which can be 
further proteolytically cleaved to form active two-chain enzyme (tcuPA). uPA is readily 
detectable in bronchioalveolar lavage and pleural fluid in mammals, and is a primary 
contributor of fibrinolytic activity in lungs (Chapman et al., 1986; Kotani et al., 1995; 
Nishiuma et al., 2004).  Tissue-type plasminogen activator (tPA), however, is not 
expressed in lung epithelial tissues and cannot be detected in luminal fluid lining the 
airways and air sacs.  Both uPA and tPA are endogenous plasminogen activators. To 
maintain fibrinolytic homeostasis, inhibitors of plasminogen activators 1 and 2 (PAI-1 
and PAI-2) and plasmin (α2-antiplasmin and α2-macroglobulin) coordinately fine tune 
the plasminogen activation system.   
The balance between plasminogen activators and their corresponding inhibitors 
is disrupted in oedematous lungs and pleural injuries, including ALI, ARDS, high altitude 
pulmonary oedema, and pleural effusions (Idell, 2008; Shetty et al., 2008; Glas et al., 
2013). Accumulating evidence from clinical studies of premature infants with ARDS and 
animal models of pleural effusions and ALI confirmed a depression in plasminogen 
activation in bronchioalveolar lavage or pleural fluid (Idell et al., 1992a; Idell et al., 
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1992b; Viscardi et al., 1992).  This is primarily attributable to a tremendous elevation in 
PAI-1 level (a prognostic biomarker) and a significant reduction in uPA and plasmin 
(Bertozzi et al., 1990; Idell et al., 1991; Sisson et al., 2002; Prabhakaran et al., 2003; 
Sapru et al., 2010). Concurrently, the balance between fluid turnover and resolution in 
the airways, alveolar spaces, and pleural cavity is lost.  Accumulation of oedematous 
fluid mainly results from fluid re-absorption that cannot be compensated by fluid leakage 
(Matthay et al., 2002; Davis & Matalon, 2007; Eaton et al., 2009). This pathogenic 
scenario can be illustrated with alveolar fluid clearance. Alveolar fluid removal is driven 
by the osmotic sodium gradient as well as electrical potential difference across the 
alveolar epithelium.  Vectorial transalveolar salt transport generates both chemical and 
electrical differences between luminal and interstitial compartments. Epithelial sodium 
channels (ENaC) at the apical membrane and ATP-consuming Na+/K+-ATPase at the 
basolateral membrane coordinately control sodium inward movement and depolarize 
the epithelial layer (Fuller et al., 1996; Ji et al., 2012).  
Reduced ENaC expression and activity were described in both oedematous 
pulmonary diseases and animal models (Matthay et al., 2002; Matthay, 2014).  
Defective lung fluid clearance has been confirmed in mice with deficient scnn1 genes 
(Hummler & Planes, 2010).  uPA and tPA decreased the severity of lung injury and 
pleural effusions (Strange et al., 1995; Stringer et al., 1998; Munster et al., 2000; 
Stringer et al., 2004; Renckens et al., 2008; Huang et al., 2012; Komissarov et al., 
2013).  Whether delivered plasminogen activators evoke ENaC-mediated oedema 
resolution, however, is unknown to date.  
The concurrent oedema formation and suppressed fibrinolysis in injured lungs 
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and pleural cavity, suggest a potential contribution of fibrinolysis to ENaC function.  
Indeed, ENaC activation by plasmin has been recently demonstrated (Passero et al., 
2008; Haerteis et al., 2012).  Intratracheal and intrapleural delivery of uPA (abbokinase) 
and tPA (alteplase) is extensively used for fibrinolytic therapy for embolisms (Wang et 
al., 2010; Marhuenda et al., 2014; Meyer et al., 2014; Piazza et al., 2015), pleural 
effusions, and empyemas (Diacon et al., 2004; Cases Viedma et al., 2006; Thommi et 
al., 2007; Froudarakis et al., 2008; Zuckerman et al., 2009; Rahman et al., 2011; 
Thommi et al., 2012; Aleman et al., 2015; Cao et al., 2015; Saydam et al., 2015).  
However, to the best of our knowledge, the effects and underlying mechanisms of tPA 
and uPA on ENaC function remain obscure. Our studies therefore aim to understand 
the molecular and pharmacological mechanisms by which these serine proteases 
resolve oedema fluid.   
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2. Central Hypothesis that links published 
works 
The central hypothesis that links my previous publications is that δ subunit-containing 
channels are essential to maintain pulmonary fluid homeostasis and fibrinolysins post-
translationally cleave ENaC to regulate transepithelial salt re-absorption. Our published 
data strongly support this hypothesis as described in Section 3. These studies were 
performed in vitro, in vivo and ex vivo with multiple cutting-edge techniques. The main 
goal of our projects is to characterize the major pathway of fluid clearance via ENaC 
and the regulation by fibrinolysis. We thus aim to confirm that 1) a novel δ ENaC 
contributes to pulmonary epithelial sodium transport; 2) fibrinolysis regulates ENaC-
mediated fluid homeostasis under physiological conditions; 3) the uPA pathway 
regulates normal ENaC function; and 4) molecular mechanisms for fibrinolysins to 
activate ENaC.  Our published works strongly support this central hypothesis. Our data 
provide paradigm-shifting information to develop innovative therapeutic strategies for 
combating both “wet” and “dry” lungs.  
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3. Significant Findings and Conclusions 
3.1 Four epithelial sodium channels are expressed in human lung epithelium 
Three ENaC subunits were first identified in mice in 1994 (Canessa et al., 1994). 
Thereafter, it has long been accepted that the native ENaC channels are composed of 
α, β, and γ subunits. The expression and function of δ ENaC subunits in the respiratory 
system has not yet been paid enough attention given the fact that α ENaC deficiency 
resulted in death of newborn mice. On the other hand, mice do not express δ ENaC (Ji 
et al., 2012). Furthermore, over expression of β ENaC caused a postnatal death due to 
developmental deficiency of the respiratory system (Mall et al., 2004). We thus 
hypothesize that δ ENaC may be a critical components of human pulmonary ENaC 
channels.   
3.1.1. Expression of δ ENaC protein in lung epithelial cells. H441 is an 
airway epithelial cell line derived originally from human stem cells, Club or Clara 
epithelial cells. It has been used to functionally study amiloride-sensitive sodium 
channels associated with ENaC in several groups, including us (Tucker et al., 1998; 
Kulaksiz et al., 2002; Lazrak & Matalon, 2003; Ji et al., 2006; Nie et al., 2009a; Han et 
al., 2010; Han et al., 2011).  To detect δ ENaC expression at the protein level, H441 
monolayers grown on filters were immunostained with a specific anti- δ ENaC antibody, 
followed by a FITC conjugated secondary antibody. We found the expression of δ ENaC 
in H441 cultures (Ji et al., 2006). α, β, and γ ENaC proteins were also detected in H441 
monolayers, in agreement with other studies (Wodopia et al., 2000; Itani et al., 2002). 
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Cells incubated with non-immune IgG and the secondary antibody did not exhibit 
immunofluorescence. Similar results were seen in A549 cells.  Our results suggest that 
δ ENaC is co-expressed with α, β, and γ ENaC proteins in human lung epithelial cells.  
3.1.2. Co-immunoprecipitation of α and γ ENaC with δ ENaC in H441 cells. 
Co-expression of δ ENaC with α, β, and γ ENaC indicates that these four ENaC 
subunits may associate with each other to form channel complexes. To test this 
hypothesis, we first detected native δ ENaC protein expression in H441 cells. δ, α, and γ 
ENaC proteins were detected as 85~90 Kb for δ and α ENaC, respectively, and 150 Kb 
for γ ENaC.  γ ENaC was found to co-immunoprecipitate with δ and α ENaC (Ji et al., 
2006). Specificity was demonstrated by Western blots with anti- γ ENaC following 
pretreatment of the anti- γ ENaC antibody with excess neutralizing peptide (Ji et al., 
2006). In addition, δ ENaC also precipitated with α ENaC subunit in H441 cells and in 
COS-7 cells following transiently transfection of hemagglutinin (HA)-tagged δ ENaC 
and α ENaC (Ji et al., 2006).  
3.1.3. Identification of a novel splicing variant for δ ENaC. We recently cloned 
a novel variant, namely, δ2 ENaC. δ2 ENaC encodes a full-length proteins comprised of 
802 amino acid residues. In comparison, the aforementioned δ ENaC, termed δ1 ENaC 
here, encodes 638 amino acid residues (Ji et al., 2012). Two genetic variants of δ ENaC 
were analyzed in human alveolar epithelial cells. We found in both alveolar type I and II 
cells, δ2 ENaC is expressed at a lower level than δ1 ENaC (Zhao et al., 2012). In some 
cases, δ1 and δ2 were present in the same alveolar cells. In addition, δ1 ENaC was also 
present in pulmonary leukocytes, in which other ENaC subunits and amiloride-sensitive 
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channels have been detected (Bubien et al., 2001).   
 
3.2 δ ENaC confers the properties of αβγ ENaC channels 
Native amiloride-sensitive Na+ channels exhibit a variety of biophysical 
properties, including variable sensitivity to amiloride, different ion selectivity, and diverse 
unitary conductances. The molecular basis of these differences has not been 
elucidated. We tested the hypothesis that co-expression of δ ENaC underlies the 
multiplicity of amiloride-sensitive Na+ conductances in epithelial cells.  
3.2.1. Cation permeability. In this sets of experiments, we tested the hypothesis 
that co-expression of δ ENaC will alter the ion selectivity of αβγ channel. We found that 
the inward amiloride-sensitive Na+ current was greater than that carried by Li+ ions.  
Much less inward and relative greater outward currents were detected when K+, Cs+, 
Ca2+, and Mg2+ were used as charge carriers.  Meanwhile, the reversal potential shifted 
leftward from depolarization voltages (10 to 20 mV) by approximately 50 to 150 mV. 
Additionally, the resting membrane potentials, which were generally above zero mV 
under current clamp configuration in oocytes perfused with Na+ (or Li+), showed 
hyperpolarization to a variable extent (Ji et al., 2004).  
To calculate the permeability ratios between Na+ and the other cations, 
amiloride-sensitive current-voltage curves were fitted with the Goldman-Hodgkin-Katz 
current equation as described previously (Ji et al., 2001).  The PX/PNa ratios of Na+ /Li+ 
/K+ /Cs+ /Ca2+ /Mg2+ were 1/0.6/0.07/0.2/0.26/0.4 for δβγ ENaC. However, they were 
1/1.2/0.02/0.29/0.31/0.21 for αβγ-ENaC and 1/0.88/0.02/0.14/0.23/0.14 for δαβγ hENaC, 
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respectively. Our results of wild type αβγ and δβγ ENaC are consistent with previously 
published observations (Canessa et al., 1994; Waldmann et al., 1995; Ji & Benos, 
2004). In particular, the normalized permeability to Li+ (PNa is 1.0) for δαβγ ENaC was 
0.88, which was distinguishable from those of αβγ (1.2) and δβγ ENaC (0.6). Significant 
differences in normalized permeabilities to the other monovalent and divalent cations 
was not observed between heterologously expressed αβγ, δβγ, and δαβγ ENaC 
channels. 
3.2.2. Amiloride sensitivity. The Ki of amiloride for δβγ ENaC is in the 
micromolar range (vs <100 nM for αβγ ENaC). Amiloride blocking of δβγ ENaC is much 
more voltage-dependent compared to αβγ channel (Ji & Benos, 2004). To determine 
amiloride sensitivity of δαβγ ENaC, we perfused oocytes with solutions containing 1nM, 
10nM, 100nM, 1µM, 10µM, 100µM, and 1mM amiloride at holding potentials ranging 
from -120 mV to +80 mV. We observed that the dose-response curves shifted rightward 
at depolarized potentials. The Ki of amiloride at -120 mV was 920 ± 185 nM, and 13,746 
± 2805 nM at +80mV, respectively, which significantly differ from those of αβγ ENaC (P 
< 0.05) (Ji et al., 2004).  
To further investigate the voltage dependence of amiloride inhibition for δαβγ 
human ENaC channel, the retrieved values for Kiamil were plotted against the membrane 
potentials (Ji et al., 2004; Ji et al., 2006). The more depolarizing the membrane 
potential, the greater the value of Kiamil. As we have previously described for αβγ and 
δβγ ENaC, positively charged amiloride interacts with ENaC in a voltage-dependent 
manner (Ji & Benos, 2004). The Ki of amiloride at 0 mV estimated by fitting the voltage-
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dependent plot with the Woodhill equation was 3.79 ± 0.2µM for δαβγ ENaC, whereas it 
was 13.1 µM and 0.33 µM for δβγ and αβγ ENaC, respectively (Ji et al., 2004).  The 
voltage sensitive fractional distance for amiloride was 0.41 (Ji et al., 2004). In 
comparison, it was 0.34 for αβγ ENaC and 0.48 for δβγ ENaC, respectively (Ji et al., 
2004; Ji et al., 2006).  
3.2.3. Unitary conductance. Because the ion permeability ratio (PNa/PLi) and 
apparent equivalent dissociation constant of amiloride for the δαβγ ENaC channel are 
the arithmetic mean of those of αβγ and δβγ ENaC, the question arose whether oocytes 
injected with δαβγ ENaC subunits express two separate populations of ENaC, that is, 
αβγ and δβγ ENaC channels, or one population of δαβγ channels with novel biophysical 
characteristics.  To address this question, on-cell patches were used to measure single 
channel conductances (Ji et al., 2004; Ji et al., 2006). Only one unitary Na+ or Li+ 
current level was observed and the corresponding slope conductances, respectively, 
were 8 ± 0.2 pS for Na+ and 7.5 ± 0.1 pS for Li+ ions. No amiloride-sensitive sub-
conductance was observed (Ji et al., 2004).  
3.2.4. Gating kinetics. We measured the mean open time (MOT) and mean 
closed time (MCT) for δαβγ-ENaC (Ji et al., 2006). We described that the MOT and 
MCT for δαβγ ENaC channels were significantly less than the corresponding values for 
αβγ and δβγ ENaC channels.  The MOT values for αβγ and δβγ ENaC were greater than 
that of δαβγ ENaC (P < 0.05). In addition, the MCT values of αβγ ENaC was almost 10-
fold of that for δαβγ ENaC (P < 0.05).  
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3.2.5. Proton activation. We found that δβγ, but not αβγ ENaC was activated by 
extracellular protons (Ji & Benos, 2004). To test the pH sensitivity of δαβγ ENaC, 
oocytes were perfused with bath solutions with neutral or acidic pH.  Similar to the δβγ 
ENaC channel expressed in oocytes, the inward current of δαβγ ENaC was activated by 
extraoocyte acidic pH in a concentration-dependent pattern (Ji et al., 2006).  The pH 
value required for half activation of the maximal pH-activated current level (EC50) was 
6.5 ± 0.1 (Ji et al., 2004). This differs from pH 6.0 for δβγ ENaC (Ji & Benos, 2004).  
3.2.6. Self-inhibition. Self-inhibition by extracellular Na+ ions is a biophysical 
hallmark of the ENaC channels (Garty & Palmer, 1997). To characterize this inherent 
biophysical property, the self-inhibition time of Na+ for δαβγ ENaC was examined (Ji et 
al., 2006). To calculate self-inhibition time, the currents at -60 mV were digitized while 
switching bath solutions from low Na+ ND96 medium (1 mM Na+ ions) to ND-96 (96 mM 
Na+ ions) medium. The current fraction from the time point for the first time to switch 
bath solution (from 1 mM to 100 mM) to the peak of current (τa) and from the peak of 
current to the time point for the second time to switch bath solution (from 100 mM to 1 
mM, τsi) was fitted with the first-order exponential function for estimating τa (activation 
time) and τsi (inactivation time), respectively (Ji et al., 2006).   
Our data shows that the inward current reaches its peak in less than 1 s followed 
by a run-down in the presence of constant external Na+ level.  The self-inhibition time 
(τsi) for δαβγ ENaC was 3,427 ± 217 ms, which was significantly greater than that of αβγ 
ENaC (2,584 ± 72 ms, P < 0.05) and but less than that of δβγ-ENaC (8,626 ± 1,541 ms, 
P < 0.01). In contrast, the activation (τa) was not changed significantly.  The αβγ ENaC 
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current displayed a steep run-down (45 % of the peak current in 12.5s) while the δβγ 
ENaC current level decreased to a less extent (12% of peak current in 12.5s) (Ji et al., 
2004). These results are consistent with measurements of rat and mouse αβγ ENaC 
expressed in oocytes (Chraibi & Horisberger, 2002; Sheng et al., 2004).  Therefore, the 
corresponding ratio of the peak and sustained currents was much less for αβγ ENAC 
compared with those of δβγ and δαβγ ENaC (P < 0.01).  
3.2.7. Dependence of PNa/PLi ratio and unitary Na+ conductance on injected 
cRNA concentrations. To determine the expression level of δ ENaC needed to confer 
the biophysical features of αβγ ENaC, we measured the PLi/PNa ratios and unitary Na+ 
conductance in oocytes co-injected various ratios of δ and αβγ ENaC cRNAs (Ji et al., 
2006). The PLi/PNa ratio in oocytes co-injected with an equivalent concentration (1δ:1α) 
of δ and α ENaC cRNAs was significantly lower when compared to that of αβγ ENaC 
(0.7 vs 2.0, P < 0.05). Even with the cRNA ratio of 1δ:10α the relative Li+ permeability 
reduced markedly. Meanwhile, the unitary Na+ conductance increased in 1/3 of patches 
in oocytes expressing 1δ:10α ENaC. A further increase (10δ:1α) in the δ subunit cRNA 
co-injected elevated the conductance closing to the level of δβγ ENaC (Ji et al., 2006). 
In toto, reverse transcription PCR revealed that δ ENaC is co-expressed with αβγ 
subunits in several cultured human epithelial cells, including lung epithelial cells (H441 
and A549), pancreatic cells (CFPAC), and colonic epithelial cells (Caco-2). Indirect 
immunofluorescence microscopy revealed δ ENaC is co-expressed with α, β, and γ 
ENaC in H441 cells at the protein level.  The biophysical and pharmacological features 
between classical αβγ and δαβγ channels are different.  We, therefore, conclude that δ 
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ENaC forms multimeric channels with αβγ subunits with novel biophysical features, 
thereby accounting at least in part, for the observed heterogeneity of biophysical 
properties of native epithelial Na+ channels (Ji et al., 2006).  
 
3.3 Urokinase contributes to fluid homeostasis in pulmonary system 
Concurrent existence of lung oedema and significant depressed fibrinolytic 
activity in oedematous lung injury indicates a link between the uPA/plasmin system and 
transepithelial fluid movement (Idell et al., 1992a; Barazzone et al., 1996; Sebag et al., 
2011; Tucker & Idell, 2013). We reported that plasminogen activator inhibitor (PAI-1) 
altered ENaC activity previously (Lazrak et al., 2009).  We also demonstrated that 
trypsin cleaved ENaC in vitro (Jovov et al., 2002).  uPA is a major contributor to the 
pulmonary fibrinolytic activity. An overwhelmingly elevated PAI-1 level in the BAL lavage 
was supposed to eliminate uPA activity (Idell, 2003; Shetty et al., 2008; Sapru et al., 
2010). However, in normal lungs, uPA is readily detectable (Shetty et al., 2008; Ji et al., 
2015). We thus hypothesize that uPA regulates transalveolar fluid clearance in vivo. To 
test this hypothesis, we utilized a mouse colony with deficient uPA gene, and the 
controls were wild type mice with the same genetic background.  Furthermore, the 
underlying mechanisms were explored in primary cell cultures.  
3.3.1. Characterization of ENaC activity in uPA knockout cells. Benzamil is a 
specific and potent inhibitor of ENaC activity (Kleyman et al., 1999). We examined 
dose-effect relationship of benzamil in mouse tracheal epithelial (MTE) monolayer cells. 
Our results suggest that the level of basal short-circuit current (Isc) in WT cells is 
approximately four fold that in uPA knockout preparations. The Isc values were inhibited 
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by increasing the administered benzamil from 10 nM to 100 µM (Chen et al., 2014).  
However, the Ki values for WT and uPA-/- cells do not differ significantly. 
3.3.2. Reduction of ENaC activity in uPA-deficient MTE cells. Inflammation 
and suppressed uPA activity are known to co-exist in injured lungs (Idell et al., 1992a; 
Barazzone et al., 1996; Sebag et al., 2011; Tucker & Idell, 2013). Based on the marked 
difference in ENaC activity between WT and uPA-/- cells, we postulated that uPA 
regulates ENaC activity in the airway epithelium. To test this hypothesis, we measured 
ENaC function in MTE monolayer cells collected from both WT and uPA-/- mice.  MTE 
cells from age- and gender-matched mice were cultured at the air-liquid interface as 
described (Chen et al., 2009). We found that basal activity in uPA-/- cells was reduced 
compared to that in WT controls.  Amiloride, a widely used inhibitor of ENaC activity, 
reduced the predominant fraction in both WT and uPA-/- cells.  In sharp contrast, the 
transepithelial resistance did not show any difference between these two groups, 
though amiloride increased the value slightly (Chen et al., 2014).  uPA deficiency 
caused a reduction of ~40 % in ENaC function (Chen et al., 2014).   
ENaC activity depends upon its phosphorylation by the cAMP/PKA signaling 
pathway. We therefore examined the effects of uPA on cAMP-activated ENaC activity.  
Cystic fibrosis transmembrane conductance regulator (CFTR) is also a target of the 
cAMP/PKA signaling pathway and functionally inter-regulates ENaC.  CFTRinh-172 was 
used to eliminate CFTR function.  Similar to the basal ENaC activity, a significant 
reduction in the cAMP-elevated ENaC activity was observed in uPA-/- cells (Chen et al., 
2014).  
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3.3.3. uPA deficiency down-regulates ENaC activity in permeabilized cells. 
Na+ ion flow through ENaC channel pore is driven by both Na+ ion gradient across the 
apical plasma membrane and Na+/K+-ATPase at the basolateral membrane.  To 
measure ENaC activity, Na+/K+-ATPase was eliminated functionally in the basolateral 
membrane-permeabilized cells. In addition, electrogenic Cl- flow via CFTR was 
completely blocked by symmetrical Cl- concentration across the apical membrane.  
Under these conditions, we reevaluated ENaC activity with a physiological Na+ ion 
gradient (Chen et al., 2014).  The rate of Na+ influx through ENaC shows a significant 
decrease in uPA-/- cells. These data, combined with those from intact monolayer cells, 
support the concept that ENaC activity in MTE cells is down-regulated in the absence of 
uPA.   
We next asked whether uPA knockout would affect Na+/K+-ATPase and indirectly 
down-regulate ENaC by eliminating the transepithelial Na+ ion gradient.  To answer this 
question, we compared Na+/K+-ATPase activity between WT and uPA-/- cells following 
apical membrane permeabilization (Chen et al., 2014).  Ouabain-inhibitable Isc fraction 
was approximately 50% that of WT cells.  Clearly, depression of the driving force for 
ENaC results in reduced ENaC activity in uPA-deficient cells. 
3.3.4. Phosphorylation of ERK1/2 and Akt by uPA. ERK1/2 and Akt are 
downstream components of the uPA/uPAR signaling pathway (Smith & Marshall, 2010). 
Furthermore, ENaC has been confirmed to be regulated by both phosphorylated 
ERK1/2 and Akt (Arteaga & Canessa, 2005; Lee et al., 2007; Lazrak et al., 2012). We 
reasoned that uPA deficiency regulated ENaC activity via modification of ERK1/2 and 
Akt phosphorylation (Figure 6).  The first set of immunoblot assays was carried out with 
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Figure 6. Diagram of the ERK1/2 and Akt as downstream molecules of the uPA. 
Signal pathway.  
lung tissues.  A significant elevation in the ratio of phosphorylated versus total proteins 
for ERK1/2 was seen in uPA-/- lysates (Chen et al., 2014).  However, alteration in the 
phosphorylation status of Akt was not observed neither in uPA-/- deficient MTE cells or 
lung homogenates.  We then repeated these intriguing observations in cultured primary 
MTE cells.  An incremental change in phosphorylated ERK1/2 proteins was found in 
uPA-deficient MTE cells.  In striking contrast, a slight decline in phosphorylated Akt 
proteins was found. Is phosphorylation of ERK1/2 a mediator for the regulation of ENaC 
activity by uPA? To address this question, we knocked down ERK1/2 using specific 
siRNAs (Chen et al., 2014). ENaC activity was restored up to approximately 90% of that 
in WT cells, indicating that uPA regulates ENaC via ERK1/2 phosphorylation. 
3.3.5. Apoptosis is not involved in the reduction of ENaC activity. It has 
been documented that manipulation of uPA gene influences cellular apoptosis 
(Hildenbrand et al., 2008; Prager et al., 2009). Reduced ENaC activity could simply be 
due to abnormal cell survival.  We addressed this issue by determining the expression 
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of caspase 8, an apoptotic marker in the WT and uPA-/- MTEs (Du et al., 2006). Neither 
full-length nor cleaved caspase protein expression was augmented (Chen et al., 2014).  
These results were supported by the transepithelial resistance measurement and 
demonstrate that the decreased ENaC activity in uPA-/- cells is not attributable to 
apoptotic transformation of the cells.  
3.3.6. Proteolysis of ENaC by uPA. Urokinase belongs to the S1 family of 
serine proteases.  The active triad is composed of histidine, aspartic acid, and serine 
residues.  Heterologously expressed human and murine ENaC proteins have been 
confirmed to be proteolytically modified by plasmin (Passero et al., 2008; Haerteis et al., 
2012).  We postulate that uPA cleaves ENaC under physiological conditions, and that 
uPA deficiency depresses proteolysis of ENaC.  To characterize a new polyclonal 
antibody against the C-terminal peptide of rat γ ENaC, proteins in Western blots loaded 
with both total and plasma membrane proteins from cells expressing mouse γ ENaC 
served as positive controls.  The construct was tagged at the N-terminal with FLAG@ 
(trademark) epitope that can be specifically recognized by a monoclonal antibody 
against FLAG epitope.  There are two specific bands (95 and 86 kDa) with anti-FLAG 
antibody, which was loaded with total proteins of cells expressing mouse γ ENaC with 
FLAG epitope.  Similarly, the polyclonal ENaC antibody raised with the C-terminal 
peptide of rat γ ENaC recognized the same signals, which were loaded with total and 
plasma membrane protein, respectively.  Importantly, this polyclonal antibody detected 
a cleaved C-terminal fragment with a size of approximately 74 kDa in wild type mouse 
lung tissues.  Furthermore, we quantitated the cleavage of γ ENaC in uPA deficient 
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lungs using β-actin as a loading control (Chen et al., 2014).  Indeed, catalysis of γ ENaC 
was significantly reduced in the lungs of uPA disrupted mice. 
3.3.7. Contribution of uPA to airway luminal fluid homeostasis. Homeostasis 
of respiratory luminal fluid is mainly regulated by ENaC (Mall et al., 2008; Mall et al., 
2010; Lazrak et al., 2011).  We postulated that uPA-mediated ENaC activity in the 
airway epithelial cells may affect fluid re-absorption.  To test this hypothesis, we 
measured fluid height at the apical surface of MTE (mouse tracheal epithelial) cultures 
using a well-characterized visualization approach (Tarran et al., 2005; Hobbs et al., 
2013). We demonstrated that the depth of apical fluid above the uPA-deficient cells was 
much greater than that of WT controls (P < 0.05) (Chen et al., 2014).   
In summary, this set of studies provides novel evidence that uPA regulates ENaC 
activity via multifaceted mechanisms that relate to clearance of airway fluids in injured 
lungs. uPA exerts its effects on proteolysis of ENaC, regulation of Na+/K+-ATPase, and 
modification of ERK1/2 signaling. This work links alterations in the expression of uPA 
activity to altered ENaC functionality in injured lungs.  
 
3.4 Urokinase plasminogen activator proteolytically cleaves γ ENaC subunits 
There are at least four ENaC subunits (α, β, δ, γ) expressed in human respiratory 
epithelial cells. The question raised from above in vivo studies is what ENaC subunit is 
catalyzed by urokinase? To date, all of three subunits have been reported to be 
proteolytically cleaved, in particular α and γ ENaC proteins (Andreasen et al., 2006; 
Planes & Caughey, 2007; Kleyman et al., 2009). δ ENaC is not believed to be cleaved 
(Haerteis et al., 2009; Giraldez et al., 2012; Ji et al., 2012). Our immunoblotting assay 
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suggests that at least fragments of native γ ENaC proteins in uPA deficient cells are 
altered (Chen et al., 2014). To further identify the target subunit for uPA, we incubated 
Xenopus oocytes heterologously expressing various combinations of human αβγ ENaC 
subunits with two-chain uPA (tcuPA).  Single chain uPA proteins were generally cleaved 
to form tcuPA with catalytic activity under physiological conditions. The cleavage of 
ENaC proteins was detected by combining functional analysis of ion channel activity 
with immunoblotting assays of catalyzed peptides. 
3.4.1. γ ENaC is cleaved by uPA. To identify what subunits are cleaved by 
tcuPA, a well-established measurement of amiloride-sensitive sodium ion flow was 
applied (Ji et al., 1998a; Ji et al., 1998b, 1999; Ji et al., 2000; Ji et al., 2001; Ji et al., 
2002a; Ji et al., 2002b). We expressed α alone, α + β, and α + γ in oocytes.  tcuPA 
slightly stimulated current level in cells expressing α ENaC alone (P > 0.05).  The 
change in cells co-expressing α + β ENaC subunits was not significant.  In sharp 
contrast, the activity of channels composed of α + γ ENaC subunits was increased 
approximately three-fold (P < 0.05).  These results indicate that the γ subunit could be a 
target for tcuPA.   
3.4.2. Identification of cleavage regions in ENaC. As proposed and confirmed 
by several groups, there are three putative cleavage domains (Rossier, 2004; Planes & 
Caughey, 2007; Kleyman et al., 2009; Rossier & Stutts, 2009).  To narrow down the 
search range for uPA cleavage sites, we constructed three deletion mutants for both α 
(α∆131-138, α∆178-193, and α∆410-422) and γ ENaC subunits (γ∆131-138, γ∆178-193, 
and γ∆410-422), and expressed them in oocytes.  We reasoned that removal of tcuPA 
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cleavage sites from these ENaC subunits, channel activity associated with these 
cleavage site-missing mutants should not be altered by tcuPA.  Intriguingly, four 
mutants, one of α ENaC and all three deletion mutants of γ ENaC subunit did not 
respond to tcuPA (Ji et al., 2015). Because the current levels between each construct 
vary before application of uPA, we thus computed fold increased in the ENaC activity, 
suggesting that uPA-specific cleavage motif may be located within these four deleted 
ectodomains.   
We then constructed V5 (C-terminal) and HA (N-terminal) tagged α (HAαV5) and γ 
ENaC (HAγV5) to examine tcuPA-mediated proteolysis combining biotinylation and 
Western blots.  What we observed is that three bands of α ENaC were recognized by 
anti-V5 monoclonal antibody.  One small fragment at 25 kDa in addition to a full-length 
signal was identified by anti-HA antibody (Ji et al., 2015).  Furthermore, three small 
bands could be visualized on 16.5% Tris-Tricine gels by anti-HA antibody.  The same 
signal patterns of α ENaC were found in the absence and presence of tcuPA, either with 
anti-carboxyl terminus (-COOH) or anti-amino terminus (-NH2) antibody.  These results 
exclude the cleavage of α ENaC proteins by tcuPA, further substantiating the functional 
analysis. 
In strict contrast to α ENaC, two peptides of γ ENaC were visualized by anti-V5 
antibody for full-length proteins (86 kDa) and endogenous furin-cleaved C-terminal 
fragments (70 kDa) in the absence of tcuPA (Ji et al., 2015).  By comparison, in the 
presence of tcuPA, C-terminal fragments with a smaller size (65 kDa) than that of furin-
cut fragments along with the full-length proteins were seen.  Strikingly different from 
anti-V5 antibody-recognized signals, proteins detected by anti-HA monoclonal antibody 
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displayed a similar pattern, either on 7.5 % SDS-PAGE gels or 16.5% Tris-Tricine gels. 
The same pattern for ENaC expression was found between controls and tcuPA-treated 
groups, indicating that the furin sites may precede the cleavage domains for tcuPA.  
Thus, the subsequent Western blots were done with anti-V5 antibody to examine uPA-
cleaved C-terminal peptides as well as full-length translations (Ji et al., 2015). 
3.4.3. An uPA substrate in γ ENaC. Several serine proteases, including 
prostasin (RKRK178), human neutrophil elastase (V182, V193), and plasmin (K189) 
trimmed the second consensus proteolysis motif (Rossier, 2004; Planes & Caughey, 
2007; Kleyman et al., 2009; Rossier & Stutts, 2009).  It is conceivable that all these 
residues are targeted by tcuPA.  This is at least the scenario for substrate-less specific 
plasmin to cleave human γ ENaC (Haerteis et al., 2012).  Indeed, the plasmin cleavage 
site composed of five amino acid residues for prostasin and one for murine plasmin 
(178RKRK181 + K189), when substituted with alanine (termed γ5A, 178AAAA181 + A189) 
was not stimulated by tcuPA even after 24 h (Ji et al., 2015).  Moreover, the tcuPA-
cleaved band disappeared compared with that of wild type channels (Ji et al., 2015).  
A series of classic studies on the specificity of uPA substrates revealed a 
consensus cleavage motif, GR↓(S>N/K/R)(A>>S) from P2 to P2’ (Ke et al., 1997a; Ke 
et al., 1997b).  We further combined in silico prediction and immunoblotting assays to 
narrow down the cleavage site.  Using the SitePrediction server (Verspurten et al., 
2009), only one hit was predicted: 177GR↓KR within the ectodomain of human γ ENaC 
with a specificity above 99%.  In strict contrast, no specific cleavage sites in human γ 
ENaC were found for tPA with its cleavage motif, (F/Y/R)GR↓R(A/G) from P3 to P2’ 
amino acid residues.  In addition, there are no predicted cleavage sites in human α, β, 
 35 
and δ ENaC proteins for uPA to meet the prediction criteria.  Does uPA cut γ ENaC 
proteins into two fragments between Arg178 and Lys179?  We validated this prediction 
combining mutagenesis, functional measurements, biotinylation, and immunoblotting 
assays.  Neither γR178A nor γK179A could be activated by tcuPA in 24 h significantly 
(Ji et al., 2015).  We anticipated that the uPA-cleaved band of R178A and K179A 
should migrate slower than that wild type if any. Intriguingly, it is the case for K179M, 
and probably K179A but not R178A.  This phenomenon is consistent with the functional 
data measured as amiloride-sensitive sodium currents (Ji et al., 2015). Combined with 
the blot for the deletion mutant, we believe that amino acid residues from P2-P2’ 
(177GRKR180) coordinately interact with uPA to serve as a catalytic triad. Of them, both 
R178 and K179 amino acid residues are critical for uPA-mediated proteolysis. 
Combined with in silico prediction, mutagenesis, electrophysiological 
measurements, and immunoblotting assays, for the first time, we demonstrate human γ 
ENaC is a new substrate for uPA. Furthermore, we identified a specific motif with 
identical sequence to the proven substrate for uPA. These novel results provide 
molecular basis for the underlying mechanisms for uPA to activate ENaC. Genetic 
variance of the cleavage sites in γ ENaC may lead to uPA-deficient like dysfunctional 
fluid clearance in the airways and lungs. 
3.5 Localization of “cutting edge” of urokinase to catalyze ENaC 
3.5.1. uPA but not tPA activates ENaC. Fibrinolytic activity is depressed in 
injured organs (e.g. in acute lung injury and pleural effusion) (Bertozzi et al., 1990; Idell 
et al., 1991; Sisson et al., 2002; Prabhakaran et al., 2003; Sapru et al., 2010). These 
organ injuries are characterized by fluid accumulation in the luminal cavities, where 
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ENaC is critical for fluid resolution (Matthay et al., 2002; Matthay et al., 2005; Eaton et 
al., 2009; Ji et al., 2012). Both uPA and tPA initiate fibrinolysis by converting 
plasminogen to plasmin. To examine the specificity of uPA on ENaC activity, we 
compared the effects of uPA and tPA (Ji et al., 2015). tcuPA stimulated ENaC activity in 
a dose-dependent manner. A linear relationship was seen between tcuPA concentration 
above 5 µg/ml (100 nM) and ENaC currents (Ji et al., 2015). Furthermore, we 
characterized the time course for the activation of ENaC function by tcuPA. ENaC 
activity was quickly elevated at 2 h, followed by a slow increment, finally reaching 
maximal activity at 8 h post-treatment. The ENaC currents subsequently declined 
slightly but were still significantly greater than the control (P < 0.05) at 24 h. The uPA 
enzyme activity was 80 and 20% of the initial level, at 8 and 24 h, respectively. 
Insufficient enzyme, altered endocytosis of channel proteins, and time-dependent 
expression of exogenous ENaC channels may contribute to the slight decline of current 
level after the 8 h time point.  
Surprisingly, neither single-chain tPA (sctPA) nor two-chain tPA (tctPA) at a dose 
of 10 ug/ml altered ENaC activity (Ji et al., 2015). Tenecteplase was tested next to 
determine whether exosite interactions contribute to a sharp difference in the effects of 
tPA and uPA on ENaC activity. Tenecteplase is a mutant variant 
(T103N/N117Q/K296A/ H297A/R298A/R299A) of tPA, which has higher than WT tPA 
fibrin specificity, and almost 2 orders of magnitude lower affinity for PAI-1 due to the 
elimination of positive charges in the 37-loop (57–59). However, neither sctPA nor tctPA 
nor tenecteplase in doses as high as 25 ug/ml affected ENaC activity (Ji et al., 2015), 
whereas enzymatic amidolytic activity toward LMW substrates and plasminogen-
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activating activity remained intact. Our study hereby adds a novel endogenous target to 
the uPA substrate pool.  
3.5.2. Catalytic triad of uPA to cleave ENaC. The two polypeptide chains of an 
uPA molecule (amino-terminal fragment (ATF) and protease domain) are connected by 
a single disulfide bond between two cysteine residues. To evaluate the contribution of 
uPA catalytic and ATF domains to activation of ENaC, a catalytically inactive S195A 
(chymotrypsin numbering) tcuPA and three uPA domain-deletion mutants, ∆kringle 
(deletion of Kringle domain), ∆CPD (deletion of Connecting Peptide Domain), and 
∆GFD (deletion of Growth Factor Domain) uPA, were compared with WT tcuPA. 
Oocytes expressing ENaC cRNA cultured in medium without uPA or its mutants were 
used as a negative control (Ji et al., 2015). Whereas inactive S195A tcuPA did not 
elevate ENaC current, all three mutant variants, which include the catalytic domain and 
possess enzymatic activity, activated ENaC. Therefore, there is only minimal (if any) 
contribution of ATF to ENaC activation by uPA (Ji et al., 2015).  
To further confirm these intriguing observations and to exclude the bias 
associated with enzymatic activity of each preparation of wild type and mutated uPA, we 
repeated these experiments by incubating oocytes with both wild type and mutant tcuPA 
preparations that, except for the S195A mutant, have equivalent enzymatic activity (Ji et 
al., 2015). Consistent with the above experiment, the S195A tcuPA (negative control for 
this set experiments) did not affect ENaC activity. These three domain-deletion mutants 
of uPA, namely, ∆kringle, ∆CPD, and ∆GFD, stimulated ENaC currents to an extent 
similar to WT tcuPA. These data demonstrate that the amino-terminal fragment is not 
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involved in the activation of ENaC by tcuPA. Moreover, the same level of enzymatic 
activity associated with both wild type and mutant tcuPA, instead of identical mass, 
determined the amplitude of ENaC currents. We pooled experimental paired data for 
WT and mutated uPA as well as tPA constructs to compute the Pearson correlation. A 
correlation co-efficient of 0.93 was derived with a P value of 3.5E-6 between tcuPA and 
ENaC activity (Ji et al., 2015). In sharp contrast, tPA enzyme activity showed no 
correlation with ENaC function. These results suggest a possible correlation between 
activated ENaC current levels and uPA enzyme activity, demonstrating that S195 is 
required for uPA to cleave ENaC. 
3.5.3. Structural interactions between catalytic sites of uPA and cleavage 
sites of γ ENaC.  The cleavage sites in the γ ENaC (R178 and K179) are located 
between α1 and α2 domains of the finger, a hypervariate region. The confident docking 
of the uPA specific cleavage site into the enzyme active center of uPA substantiates 
their protein-protein interactions (Ji et al., 2015).  A network of hydrogen bonds within 
the catalytic triad of uPA was visualized (Figure 7).  Importantly, hydrogen bonding pairs 
are detected between His57 (uPA) and Lys179/Arg180 (ENaC), and Ser195 (uPA) and 
Arg178/Lys179 (ENaC).  Beside, Thr176 (ENaC) interacts with His99 (uPA).  Arg178 
(ENaC) protrudes down into a deep cavity and interacts with other residues in the 
bottom of the cavity.  Proteolysis of ENaC by uPA could be divided into two steps: 
acylation and deacylation (Neitzel, 2010). The Ser195 of uPA, together with His and 
Asp, serves as a nucleophilic “edge” to separate the Arg178 from Lys179 of γ ENaC, 




Figure 7. Structural interactions between uPA and human γ ENaC. A, surface view of the 
catalytic triad of uPA (Protein Data Bank code 1W12). The triad residues (Asp-102, His-57, 
and Ser-195) along with His-99 line the back of the enzyme active center. Inset, measures 
of hydrogen (green and white dashed lines) bonds among amino acid residues composed 
of the catalytic triad. B, docking of the cleavage site (P3–P2’) of γ ENaC to the enzyme 
active pore of uPA. C, uPA-induced cleavage of the γ ENaC. Arg-178 and Lys-179 are 
located between the α1 and α2 domains. Domain coloration is as follows: transmembrane 
domains 1 and 2 (TM1 and TM2) (red), wrist (red), palm (blue), knuckle (cyan), finger 
(purple), thumb (green), and β (orange). The three-dimensional uPA-cleaved sites from P3 
to P2’ in human  ENaC (TGR↓KR) was generated by using “Tools>Build and Edit 
Protein” in Discovery Studio Visualizer version 4.0. Following removal of the ligand from 
uPA, docking of the cleavage site in ENaC to uPA was performed with Autodock Vina 
version 1.1.1 in a Pyrx (version 0.85) environment. The top-ranking pose with minimal 
energy in the docking results was selected and saved as a Protein Data Bank file. Final 
presentation was accomplished with Discovery Studio Visualizer version 4.0 by inserting the 
selected docking pose of the cleavage sites into the catalytic triad of uPA protein. The 
docking structure of uPA and cleavage site was further energy-minimized by “clean 
geometry.” The uPA-ENaC interactions between the enzymatic domain and cleavage sites 
were visualized by a “non-bond interaction monitor” for a ligand-receptor mode. Adapted 
     
3.6 Urokinase augments opening channel density and opening time of channels 
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3.6.1. uPA strengthens the open conformation of ENaC. A two-state model 
(closed-open) has been proposed to analyze the gating kinetics of ENaC channels 
(Chraibi & Horisberger, 2002). We postulated that tcuPA opens closed channels and 
facilitates maintenance of activated ENaC in the open state.  To analyze this, the gating 
kinetics is computed by measuring self-inhibition of external Na+ ions (Ji et al., 2015).  In 
addition to stable channel activity (reflected by sustained current level), the maximal 
channel activity (measured as peak current) was significantly greater than in control 
cells.  The ratio of sustained over maximal current levels is approximately 0.5 for ENaC 
channels in control cells, which is consistent with previous observations (Sheng et al., 
2004; Sheng et al., 2007; Molina et al., 2011).  By comparison, our results showed that 
the value was close to 1.0 following exposure to tcuPA.  These studies suggest that 
self-inhibition is diminished by tcuPA.  There are two components of self-inhibition: a 
fast phase followed by a slow phase (Garty & Benos, 1988; Ji et al., 2015). The rate of 
activation process after incubation with tcuPA was almost an order of magnitude faster 
than that for untreated cells (1.17 and 11.9 s-1 for control and tcuPA treatment, 
respectively). Moreover, treatment with tcuPA completely eliminated inactivation 
(inactivation rate was reduced by tcuPA from 0.56 s-1 to 0.0 s-1).  In addition, even with 
switched gating rates between control and tcuPA-treated cells, the simulated maximal 
current level at the full open state for controls was still much lower than the sustained 
current magnitude of tcuPA-challenged cells.  These observations could not simply be 
explained by full opening of activated channels in untreated cells.  On the other hand, 
irreversibility of the effect of tcuPA on ENaC gates most likely reflects cleavage of ENaC 
by tcuPA resulting in transition to the “open” conformation of the channel.  
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3.6.2. uPA activates “silent” channels. Channel activity recorded in whole-cell 
mode is the product of single channel activity and unitary conductance.  The latter was 
not altered during self-inhibition, as has been demonstrated by self-inhibition mutations 
(Sheng et al., 2004; Molina et al., 2011).  Single channel activity is the product of open 
probability and electrically detectable channel density.  The simulation leads us to ask 
whether there is a potential increment in functional channel density.  The functional 
channel density was computed as we described recently (Ji et al., 2015).  Our 
calculation found that the channel number that could be detected per unit area was 410 
channels /μm2 post uPA exposure.  It is five-fold greater than that in control cells (82 
channels/μm2).  It appears that uPA increases functional channel density at the plasma 
membrane.  This is supported by studies of other serine proteases (Caldwell et al., 
2004, 2005; Diakov et al., 2008).  
3.6.3. uPA optimally increases opening time. MTSET is a thiol-modifying 
reagent that activates αβS520Cγ channels almost completely as evidenced by an open 
probability of nearly 1.0 (Goldfarb et al., 2006).  If uPA activates ENaC activity via an 
increment in opening time, with a mechanism similar to that mediated by MTSET, then 
uPA should not alter ENaC whole-cell currents in MTSET-pretreated cells expressing 
αβS520Cγ channels. Our results indicate that while MTSET does increase channel 
activity in untreated cells to a level similar to that in uPA-incubated cells (Ji et al., 2015), 
it does not affect uPA-activated ENaC activity. These observations provide direct 
evidence for uPA maintenance of ENaC channels in the fully open state, with a resultant 
effect equivalent to that of MTSET.  
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3.7 Proteolysis is the mechanism to elevate ENaC activity to the utmost level vs 
self-inhibition releasing agents 
Cpt-cAMP, as a cell permeable specific PKA activator has long been used for 
studying epithelial Na+ channels.  Chraibi and colleagues found that the compound 
specifically activated guinea pig but not rat ENaC in oocytes (Chraibi et al., 2001).  
Furthermore, a key responsive domain in guinea pig α subunit (Ile481) was identified 
(Renauld et al., 2008).  Human ENaC responded to cpt-cAMP in a dose-dependent, 
time-independent, and reversible manner.  In addition to these heterologous channels, 
amiloride-sensitive, cpt-cAMP activated cation channels were also reported in human 
Clara cells (H441) and human lymphocytes in a similar manner (Bubien et al., 1996; 
Bubien et al., 1998; Bubien et al., 2001; Chen et al., 2009).  To date, the interpretation 
for the acute activation of both native and heterologous human ENaC activity by cpt-
cAMP is still limited to the mediation of the cAMP/PKA pathway.  A number of critical 
amino acid residues are involved in governing self-inhibition.  External sodium self-
inhibition is an intrinsic feature of ENaC. A rapidly increase in extracellular sodium ions 
to a physiological concentration (150 mM for mammals and 100 mM for amphibians) 
generates a maximal peak current in seconds, and then the permeability of ENaC to 
Na+ ions is gradually reduced to a relatively stable level with a current level of 
approximately half of the maximal value. This phenomenon is called extracellular 
sodium self-inhibition of ENaC activity.  It differs from the down-regulation of ENaC 
activity by slowly accumulating intracellular Na+ content in a feedback manner.  External 
Na+ self-inhibition is a crucial mechanism to limit overwhelming salt absorption to 
prevent a quick raise in epithelial cell volume and blood pressure.  Sheng and co-
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workers identified the cysteine and histidine residues in α and γ subunits were critical 
(Sheng et al., 2002; Sheng et al., 2007).  Very recently, this group provided strong 
evidence that αGly481 and γMet438 resided in the thumb domain were functional 
determinants of self-inhibition (Maarouf et al., 2009).  In addition to the relief of self-
inhibition, the external ligand-like compounds activated ENaC channels analog to serine 
proteases (Planes & Caughey, 2007; Kleyman et al., 2009; Rossier & Stutts, 2009). 
3.7.1. cpt-cAMP cannot activate cleaved ENaC by fibrinolysin. We 
hypothesize that uPA and cpt-cAMP activate ENaC with variant mechanisms and to a 
different extent.  We tested the effects of cpt-cAMP on fully opened channels in cells 
exposed to protease-plasmin (Passero et al., 2008; Svenningsen et al., 2009a; 
Svenningsen et al., 2009b). Our previous studies showed that external cpt-cAMP 
stimulated human, but not rat and murine, αβγ ENaC in a dose-dependent and external 
sodium concentration-dependent fashion (Molina et al., 2011). ENaC mutations that 
abolished self-inhibition (βΔV348 and γH233R) almost completely eliminated cpt-cAMP 
mediated activation. In contrast, mutations that both enhanced self-inhibition and 
elevated cpt-cAMP sensitivity increased the stimulating effects of the compound. Our 
above data confirmed that cpt-cAMP acts as a ligand to regulate heterologous ENaC by 
relieving self-inhibition. Edelheit et al studied alanine mutations in 17 conserved 
charged residues of ENaC and found that these residues are involved in conformational 
changes that lead to channel constriction and to the sodium self-inhibition response 
upon sodium ion flooding (Edelheit et al., 2014). Similarly, our recent data showed that 
elimination of self-inhibition of αβγ ENaC may be a novel mechanism for CPT-cGMP to 
stimulate salt reabsorption in the human epithelium (Han et al., 2011). 
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3.7.2. Cleavage abolishes cpt-cAMP-mediated ENaC activation in human 
lung epithelial cells. To corroborate the findings in oocytes, we evaluated the effects of 
cpt-cAMP on native ENaC in human lung epithelial cells (H441 monolayers), in which 
biochemically and physiologically detectable ENaCs were evoked by cpt-cAMP (Chen 
et al., 2009).  cpt-cAMP activated amiloride-inhibitable Isc levels by approximately 8% 
(Molina et al., 2011), which was much less than that for cloned ENaC in oocytes (2 
fold).  It is possible that ENaC proteins in carcinomatous H441 cells probably have been 
cleaved by overexpressed proteases (McMahon & Kwaan, 2008; Shetty et al., 2008).  
We thus incubated cells with protease inhibitors for 12 h.  As anticipated, cpt-cAMP 
increased Isc level up to 2-fold in cells pretreated with protease inhibitors (Molina et al., 
2011). 
 
3.7.3. CPT-cGMP ligand docking to different ENaC domains. In our previous 
experiment, we constructed mutants abolishing (βV348 and γH233R), or augmenting 
(αY458A and γM432G), ENaC self-inhibition (Han et al., 2011; Molina et al., 2011). The 
mutations eliminating self-inhibition resulted in a loss of response to CPT-cGMP, 
whereas those enhancing self-inhibition facilitated the stimulatory effects of this 
compound. Our analysis shows the potential binding sites for the CPT-cGMP ligand in 
ENaC domains that are crucial for self-inhibition. βV348 is located in the center of the 
palm region of the subunit, and γH233 is located in the vicinity of the putative binding 
site for protons. These domains potentially directly or allosterically interact with CPT-
cGMP.  
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3.7.4. CPT-cGMP and self-inhibition. Human serum cGMP level is 6 nM and 3-
time greater in human bronchioalveolar lavage (Arias-Diaz et al., 1994).  It appears that 
cGMP may serve as an autocrine and paracrine to regulate ENaC function.  However, 
the effective dose for CPT-cGMP and CPT-cAMP to blunt self-inhibition is micromolar, 
suggesting an uncertain physiological role for cGMP and analogs. A large dose of 
cGMP compound (1 mg/kg, i.v.) was administered to pigs as reported by a pre-clinical 
trial (Sandera et al., 2000), and numerous preclinical studies (from 100 mM to 2 mM) 
(Jain et al., 1998; Kemp et al., 2001; Chen et al., 2008).  It is therefore feasible to apply 
aerosolized nucleotides to mitigate oedematous lung injury.  We have demonstrated 
that CPT-cGMP up-regulates ENaC via two mechanisms: release self-inhibition 
externally and activates ENaC through the cGMP/cGKII pathway intracellularly (Han et 
al., 2011).  Thus, these compounds could regulate sodium absorption via either or both 
mechanisms in a cell permeability-dependent manner.  Administration of cAMP could be 
a potent pharmaceutical treatment for oedematous lung injury (Chen et al., 2009), and 
cGMP may have similar potential. cGMP increased in murine and rat lungs both in vivo 
and in vitro following nitric oxide (NO) application (Hardiman et al., 2004), and increased 
cGMP may augment the cGMP-sensitive pathway for lung fluid removal from alveolar 
sacs (Sakuma et al., 2004). Our previous study demonstrated for the first time that 
PKGII is an ENaC activator in non-ciliated bronchial secretory cells (Nie et al., 2009b). 
Accordingly, upregulation of the rate-limiting ENaCs in respiratory epithelial cells by 
specific PKGII activators may be a potent clinicopharmaceutical strategy for alleviating 
airspace flooding in fatal oedematous lung diseases. The observation of our previous 
study that specific moieties of 8-pCPT-cGMP are required for activating ENaC may 
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provide pivotal information for developing potential ENaC channel openers structurally 
related to 8-pCPT-cGMP, which would be extremely useful for treating diseases 
associated with lower ENaC function. We postulate that when the tight epithelial layer is 
damaged, for example, in injured lungs, even though the mixture of extracellular matrix 
proteins, including collagens, albumin, and fibrins, will seal the epithelial cell-free 
alveolar surface, the potency of ENaC stimulator will be limited significantly.  Therefore, 
the integrity of the tight alveolar epithelium should be a key factor to be considered for 
the usage of ENaC agonists.  The anticipated restore of alveolar fluid clearance may be 
seen at the earlier stage of ALI and lung oedema mainly caused by injured pulmonary 
vasculature or post regeneration of alveolar epithelium by stem cells/progenitors. 
3.7.5. Specific self-inhibition domains differ from uPA cleavage sites. 
His(88) and Asp(516) of the γ subunit play a role in the Zn2+ regulating sodium self-
inhibition mentioned above. Recent studies showed that palmitoylation of the γ subunit 
activates ENaC by increasing the open probability of the channels (Mukherjee et al., 
2014). ENaC mutants with the mutations γC33A, γC41A, or γC33A/C41A have 
significantly enhanced sodium self-inhibition and reduced open probability compared 
with wild type ENaCs, suggesting that ENaC palmitoylation is an important post-
translational mechanism of channel regulation. Exon 11 within the human α, β, and γ 
ENaC genes encodes structurally homologous yet functionally diverse domains, and 
exon 11 in the α-subunit encodes a module that regulates channel gating (Chen et al., 
2014). In contrast to the other mutations, γL511Q largely eliminated the sodium self-
inhibition response, reflecting a down-regulation of ENaC open probability by 
extracellular sodium (Chen et al., 2013). γL511Q is a gain-of-function human ENaC 
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variant and it enhances ENaC activity by increasing channel open probability and 
dampens channel regulation by extracellular sodium and proteases (Chen et al., 2013). 
3.7.6. Self-Inhibition as an alternative approach to fibrinolysins. Divergent 
targeting subunits and critical domains indicate that self-inhibition releasing reagents 
and fibrinolysins can be used as potential therapeutic strategies complementarily. 
Distressed transapical sodium transport occurs in injured lungs, for example, acute lung 
injury (ALI) and acute respiratory distress syndrome (ARDS) (please see classical 
reviews (Matalon et al., 2002; Matthay et al., 2002; Berthiaume & Matthay, 2007; Eaton 
et al., 2009; Matalon et al., 2015)).  Apical ENaC contributes to up to 70% of 
transepithelial sodium transport in mammalian lungs under physiological conditions.  
This critical process is sensitive to aspirated pollutants, allergens, pathogens, and 
bacterial endotoxins.  In addition to increased leaking through alveolar microvascular 
endothelium (indirect ALI), lung oedema ususally results from reduced oedema fluid 
resolution via ENaC (direct ALI).  ENaC is a promising target for developing new 
therapeutical strategies to alleviate lung oedema, at least for the phenotype of direct ALI 
(Giraldez et al., 2013; Czikora et al., 2014). 
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4. Theoretical Framework  
4.1. How and in what respect the work has made a significant and 
coherent contribution to knowledge. It is widely accepted that apical ENaC is 
composed of αβγ three subunits, given the fact that mice with deficient α ENaC (scnn1a 
gene) died after birth (Hummler et al., 1996; Hummler & Vallon, 2005). The current 
concept is that pulmonary α ENaC function is amplified by βγ counterparts. Based on 
these earlier observations, it has been assumed that the fourth ENaC, that is, δ ENaC 
may not have a role in human lungs. Of note, the scnn1d gene is a pseudogene in 
murine but expressed in humans. On the other hand, infants carrying “loss-of-function” 
genetic mutants of scnn1a did not have respiratory distress syndrome. One explanation 
is scnn1a may have unknown functions that cause death. An alternative possibility is 
that δ ENaC may compensate the salt transport function in scnn1a deficient infants. The 
contributions of δ ENaC has long puzzled ENaC researchers due to lack of animal 
models.  Our publications systematically characterized the expression and function of δ 
ENaC in pulmonary epithelium with complimentary techniques and models. Our studies 
clearly demonstrate that δ ENaC is approximately expressed in alveolar epithelial cells 
and function in a way similar to α ENaC. Our results for the first time outline the role of δ 
ENaC in pulmonary epithelial cells and shift the current concept about the components 
of apical ENaC channels. 
Albeit fibrinolysins have been applied to pulmonary diseases, their mechanisms 
remain obscure, in particular for urokinase and plasmin. Our innovative studies for the 
first time demonstrate: 1) urokinase deficiency reduced ENaC function via a reduction in 
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Na+/K+-ATPase, ERK1/2 phosphorylation, and cleavage of γ ENaC subunit in vivo; 2) 
urokinase but not tissue-type plasminogen activator (tPA) up regulates human ENaC 
function in a dose-, time- and catalytic activity-dependent manner; 3) urokinase 
proteolytically cleaves γ ENaC subunit (R178↓K179) into two fragments; 4) urokinase 
augments activation rate and eliminates “silent” channels; 5) plasmin stimulates ENaC 
in a way similar to urokinase; and 5) a nucleotide (cpt-cAMP and CPT-cGMP) activates 
ENaC by releasing external sodium inhibition, differing from aforementioned 
mechanisms for fibrinolysins.  
 
4.2. Impact. Abnormal fluid regulation in the respiratory system is the major 
pathological characteristics of both “dry” and “wet” lungs.  Dehydration of the airways 
and the airspaces is associated with cystic fibrosis, chronic obstructive pulmonary 
disease (COPD), and genetic diseases with gain-of-function mutants of ENaC (Boucher, 
2007; Mall et al., 2010; Zhao et al., 2014; Mall, 2016).  Pulmonary oedema is a life-
threatening clinical disorder. Cardiogenic pulmonary oedema (hydrostatic oedema) is 
caused by cardiovascular diseases, in particular heart failure.  Noncardiogenic oedema 
results from systemic or pulmonary infection, brain trauma (neurogenic), side-effects of 
medicines, and high altitude (HAPE). ENaC contributes to ~70 % of alveolar fluid 
clearance and re-absorption of airway surface fluid. Our studies shift the current 
concept of the pulmonary epithelial sodium transport pathway. Our data improve our 
understanding in the pathogenesis of pulmonary oedema, and our knowledge in the 
physiological functions and pathogenic role of fibrinolysin-regulated ENaC in pulmonary 
 50 
oedema. Our novel results provide cellular and molecular basis for the use of 
fibrinolysins to oedematous lung diseases.  
 
4.3. Methodologies. We combined state-of-the-art electrophysiological (the 
voltage clamping, Ussing chamber, and patch clamping assays), contemporary 
biochemical (biotinylation, immunoblotting, ELISA, and immunofluorescent scoping), 
molecular biological approaches (mutagenesis, RT-PCR, in silico prediction, and in vitro 
cRNA), preclinical tests (alveolar fluid clearance, ventilation, in vivo intratracheal 
instillation, and histology), and leading edge techniques of gene modification (knockout, 
shRNA knock down, transgenic) to study the pharmaceutical mechanisms of 
nucleotides and fibrinolysins-mediated regulation of ENaC activity.  The genetically 
engineered animals were used for in vivo studies, human lungs for ex vivo and in situ, 
primary cultures for in vitro, and expression system (Xenopus oocyte) for advanced 





Figure 8.  Graphical abstract to summarize key findings. tcuPA, two-chain urokinase 
plasminogen activator; PKGII, protein kinase G isoform 2; ENaC, epithelial sodium 
channels; HBE, human bronchial epithelial cells; ATI, alveolar type I cells; ATII, alveolar 
type II cells; N, ENaC channel density; Po, open probability; ASF, airway surface fluid.  
5. Summary/Conclusions 
In summary, our results for the first time demonstrate that 1) δ ENaC is crucial to 
maintain fluid homeostasis in the airways and the airspaces; 2) pulmonary fibrinolytic 
activity regulates fluid homeostasis by proteolytically cleaves apical located ENaC 
proteins. Our data explain the species differences in the scnn1a deficiency-associated 
respiratory distress syndrome between human and mice, and in the pharmaceutical 
efficiency and tissue dependence between tPA and uPA.  In ENaC-expressing epithelial 
and mesothelial tissues, e.g., the airways, lungs, pleural cavity, kidney, and distal colon, 
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it should be kept in mind that either endogenous or administered uPA may dehydrate 
the lumen through excessive activation of ENaC-mediated salt/fluid retention (Figure 8). 
For the first time, we demonstrate that cpt-cAMP and CPT-cGMP activate pulmonary 
ENaC by eliminating self-inhibition. Conclusively, our publications suggest that uPA, 
cpt-cAMP, and CPT-cGMP may be a novel generation of ENaC activators to mitigate 
lung oedema and other oedematous pulmonary diseases.  
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6. Contributions made by the candidate 
 By collaborating with a group of investigators on campus and worldwide, the first 
set of experiments was designed to characterize the expression and function of δ ENaC 
as well as a splicing variant in human lung epithelial cells (Ji et al., 2006; Ji et al., 2012; 
Zhao et al., 2012). Furthermore, I found that δ ENaC conferred the biophysical and 
pharmacological properties of “classical” αβγ ENaC channels when four ENaC subunits 
are co-expressed in Xenopus oocytes heterologously (Ji et al., 2006). These 
experiments were completed by collaborating with Drs. Zhao, Nie, Su, Han, Chang, 
Matalon, Kedar, Barbry, Smith, and Benos. 
 
The second set of experiments was set out to examine the regulation of ENaC by 
uPA in primary mouse tracheal epithelial cells (MTE).  The central hypothesis is that 
urokinase-like plasminogen activator (uPA) regulates ENaC function in airway epithelial 
cells. We found that both basal and cAMP-activated Na+ flows through ENaC were 
significantly reduced in uPA-deficient cells.  The reduction in ENaC activity was further 
confirmed in basolateral membrane permeabilized cells.  A decrease in the Na+/K+-
ATPase activity could contribute to the attenuation of ENaC function in intact monolayer 
cells. Dysfunctional fluid resolution was seen in uPA-disrupted cells. Administration of 
uPA and plasmin partially restores ENaC activity and fluid re-absorption by MTE cells.  
ERK1/2, but not Akt phosphorylation was observed in the cells and lungs of uPA-
deficient mice.  On the other hand, cleavage of γ ENaC is significantly depressed in the 
lungs of uPA knockout mice. Expression of caspase 8, an apoptosis molecule, however, 
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did not differ between wild type and uPA-/- mice.  In addition, uPA deficiency did not alter 
transepithelial resistance.  This is the first report demonstrating that urokinase up-
regulates ENaC activity in vivo and in vitro (Chen et al., 2014). These experiments were 
completed by collaborating with Drs. Chen, Zhao, Bhattarai, Dhiman, Shetty, and Idell. 
 
The third set of experiments was to explore the underlying pharmacological 
mechanisms for uPA to up regulate ENaC.  The hypothesis is that uPA may activate 
ENaC through proteolysis.  My results show that two-chain urokinase (tcuPA) strongly 
stimulates heterologous human αβγ ENaC activity in a dose- and time-dependent 
manner.  This activity of tcuPA was completely ablated by PAI-1. Furthermore, a 
mutation (S195A) of the active site of the enzyme also prevented ENaC activation.  By 
comparison, three truncation mutants of the amino terminal fragment of tcuPA still 
activated ENaC. uPA enzymatic activity was positively correlated with ENaC current 
amplitude prior to reaching the maximal level.  In sharp contrast to uPA, neither single-
chain tPA nor derivatives, including tctPA and tenecteplase, affected ENaC activity.  
Furthermore, γ but not α ENaC subunit was proteolytically cleaved (177GR↓KR180) by 
tcuPA.  In summary, the underlying mechanisms of urokinase-mediated activation of 
ENaC include release of self-inhibition, proteolysis of γ ENaC, incremental increase in 
opening rate, and activation of closed (electrically “silent”) channels.  In addition, 
plasmin activated ENaC in a similar way. These studies for the first time demonstrate 
multifaceted mechanisms for fibrinolysin-mediated up-regulation of ENaC (Ji et al., 
2015), which form the cellular and molecular rationale for the beneficial effects of 
urokinase and plasmin in mitigating pulmonary oedema and pleural effusions.  These 
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experiments were completed by collaborating with Drs. Zhao, Komissarov, Chang, Liu, 
and Matthay.  
Finally, I characterized the potential mechanisms for the interactions between 
proteolysis and other external ligands, including inhibitory peptides, CPT-cGMP and cpt-
cAMP (Nie et al., 2010; Han et al., 2011; Molina et al., 2011). I hypothesized that serine 
proteases fully open the gate of ENaC channels, while other ENaC activators or 
external ligands partially stimulate channel activity.  Our results show that CPT-cGMP 
and cpt-cAMP activate ENaC function through release of external sodium self-inhibition. 
In contrast, serine proteases cleave the extracellular loop of ENaC proteins and remove 
“inhibitory peptides”, which is located closely to the first transmembrane domain. ENaC 
channels treated with serine proteins were on longer activated by these external 
ligands.  In strict contrast, in the presence of CPT-cGMP or cpt-cAMP, serine proteases 
were able to activate ENaC activity to a maximal extent.  Clearly, our studies 
demonstrate that proteases are the most potent ENaC activators.  These experiments 
were completed by collaborating with Drs. Zhao, Komissarov, Chang, Liu, and Matthay. 
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Contributions to 4 of 105 publications 
1. Ji HL, Zhao R, Komissarov AA, Chang Y, Liu Y, Matthay MA. Proteolytic 
regulation of epithelial sodium channels by urokinase plasminogen activator: 
cutting edge and cleavage sites. Journal of Biological Chemistry. 2015 Feb 27; 
290(9): 5241-55. PMID: 25555911. 
Word count: 11,526. 
My contribution: 80%. 
The nature (role) of contributions: I initiated the concept, organized and 
coordinated team work, designed each experiment. All of functional evaluations 
using the two-electrode voltage clamp techniques and in silico analysis (Figures 
1-4, 8A & B) were performed by myself. Immunoblotting assays and fibrinolysin 
activity were completed by the collaborators under my supervision (Figures 5-7, 
8C & D). I also analysed each experiment, plotted all figures (Figures 1-9), 
drafted each version of the manuscript, submitted the paper and prepared 
responses to the reviewers' critiques. All of experiments were done within my 
laboratory. 
 
2. Chen Z, Zhao R, Zhao M, Liang X, Bhattarai D, Dhiman R, Shetty S, Idell S, Ji 
HL. Regulation of epithelial sodium channels in urokinase plasminogen activator 
deficiency. American Journal of Physiology Lung Cellular and Molecular 
Physiology. 2014, Oct 15; 307(8): L609-17. PMID: 25172911. 
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Word count: 7,569. 
My contribution: 60%. 
The nature (role) of contributions: I initiated the concept, organized and 
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